Shanghai Fosun Pharmaceutical (02196) new drugs included in the national medical insurance catalog and commercial insurance innovative drugs catalog.

Shanghai Fosun Pharmaceutical (02196) has announced that, based on the "National Basic Medical Insurance, Birth Insurance, and Industrial Injury Insurance Drug Catalogue (2025)" released by the National Medical Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025 (referred to as the "2025 National Medical Insurance Catalogue") and the first release of the "Commercial Health Insurance Innovative Drug Catalogue (2025)" (referred to as the "Commercial Health Insurance Innovative Drug Catalogue"), several products of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and its subsidiaries/units (referred to as "the Group") have been newly included or had their annotations adjusted. The relevant details are announced as follows: The 2025 National Medical Insurance Catalogue and the Commercial Health Insurance Innovative Drug Catalogue will be implemented from January 1, 2026. The specific medical insurance payment standards, medical insurance reimbursement details, and negotiation drug agreement validity period of the 2025 National Medical Insurance Catalogue must be based on the information announced by the National Medical Security Administration and other relevant government departments. The total sales revenue for the newly included or annotated drugs in the previous fourth quarter of 2024 and the first three quarters of 2025 amounted to approximately RMB 401 million and RMB 892 million respectively, accounting for approximately 0.98% and 3.04% of the Group's business income during the same period. The new inclusion in the 2025 National Medical Insurance Catalogue/Commercial Health Insurance Innovative Drug Catalogue is expected to further improve the accessibility of these drugs, reduce the burden on patients, and facilitate the market expansion and sales promotion of these drugs, which is anticipated to have a positive impact on the Group's future annual performance.